AGEN

Company Overview — What Does AGENUS INC Do?

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts. AGENUS INC (AGEN) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Garo H. Armen and employs approximately 440 people, headquartered in LEXINGTON, Massachusetts. With a market capitalization of $131M, AGEN is one of the notable companies in the Healthcare sector.

AGENUS INC (AGEN) Stock Rating — Reduce (April 2026)

As of April 2026, AGENUS INC receives a Reduce rating with a composite score of 34.7/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.AGEN ranks #2,345 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, AGENUS INC ranks #281 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

AGEN Stock Price and 52-Week Range

AGENUS INC (AGEN) currently trades at $4.24. The stock lost $0.21 (4.7%) in the most recent trading session. The 52-week high for AGEN is $7.34, which means the stock is currently trading -42.2% from its annual peak. The 52-week low is $1.38, putting the stock 207.2% above its annual trough. Recent trading volume was 524K shares, suggesting relatively thin trading activity.

Is AGEN Overvalued or Undervalued? — Valuation Analysis

AGENUS INC (AGEN) carries a value factor score of 26/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The trailing price-to-earnings ratio is 1.49x, compared to the Healthcare sector average of 23.63x — a discount of 94%. The price-to-sales ratio is 1.48x, compared to 1.66x for the average Healthcare stock.

At current multiples, AGENUS INC trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

AGENUS INC Profitability — ROE, Margins, and Quality Score

AGENUS INC (AGEN) earns a quality factor score of 26/100, signaling below-average profitability metrics relative to the broader market. Return on assets (ROA) comes in at -26.3% versus the sector average of -33.1%.

On a margin basis, AGENUS INC reports gross margins of 98.9%, compared to 71.5% for the sector. The operating margin is -65.2% (sector: -66.1%). Net profit margin stands at -70.7%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 28.6% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

AGEN Debt, Balance Sheet, and Financial Health

Balance sheet data for AGEN is evaluated through our stability factor. The current ratio is 0.41x, which may signal near-term liquidity tightness. Total debt on the balance sheet is $45M. Cash and equivalents stand at $3M.

AGEN has a beta of 1.38, meaning it is more volatile than the broader market — a $10,000 investment in AGEN would be expected to move 38.0% more than the S&P 500 on any given day. The stability factor score for AGENUS INC is 21/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

AGENUS INC Revenue and Earnings History — Quarterly Trend

In TTM 2026, AGENUS INC reported revenue of $105M and earnings per share (EPS) of $0.00. Net income for the quarter was $-60M. Gross margin was 98.9%. Operating income came in at $-66M.

In FY 2025, AGENUS INC reported revenue of $114M and earnings per share (EPS) of $0.00. Net income for the quarter was $-3M. Gross margin was 99.1%. Revenue grew 10.4% year-over-year compared to FY 2024. Operating income came in at $-20M.

In Q3 2025, AGENUS INC reported revenue of $30M and earnings per share (EPS) of $2.00. Net income for the quarter was $64M. Gross margin was 97.9%. Revenue grew 20.4% year-over-year compared to Q3 2024. Operating income came in at $-5M.

In Q2 2025, AGENUS INC reported revenue of $26M and earnings per share (EPS) of $-1.00. Net income for the quarter was $-30M. Gross margin was 99.1%. Revenue grew 9.3% year-over-year compared to Q2 2024. Operating income came in at $-17M.

Over the past 8 quarters, AGENUS INC has demonstrated a growth trajectory, with revenue expanding from $24M to $105M. Investors analyzing AGEN stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

AGEN Dividend Yield and Income Analysis

AGENUS INC (AGEN) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

AGEN Momentum and Technical Analysis Profile

AGENUS INC (AGEN) has a momentum factor score of 54/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 24/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 50/100 reflects moderate short selling activity.

AGEN vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, AGENUS INC (AGEN) ranks #281 out of 838 stocks based on the Blank Capital composite score. This places AGEN in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing AGEN against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full AGEN vs S&P 500 (SPY) comparison to assess how AGENUS INC stacks up against the broader market across all factor dimensions.

AGEN Next Earnings Date

No upcoming earnings date has been announced for AGENUS INC (AGEN) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy AGEN? — Investment Thesis Summary

The quantitative profile for AGENUS INC suggests caution. The quality score of 26/100 flags below-average profitability. The value score of 26/100 indicates premium valuation. High volatility (stability score 21/100) increases portfolio risk.

In summary, AGENUS INC (AGEN) earns a Reduce rating with a composite score of 34.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on AGEN stock.

Related Resources for AGEN Investors

Explore more research and tools: AGEN vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare AGEN head-to-head with peers: AGEN vs AZN, AGEN vs SLGL, AGEN vs VMD.